» Articles » PMID: 9099183

Duration of Glutamate Release After Acute Ischemic Stroke

Overview
Journal Stroke
Date 1997 Apr 1
PMID 9099183
Citations 56
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Purpose: High levels of glutamate in plasma and cerebrospinal fluid (CSF) have been demonstrated in patients with acute ischemic stroke. The duration of this excitatory amino acid release has not been studied, and therefore the window of opportunity of treatment with glutamate antagonists is unknown. The aim of this investigation was to study the duration of the glutamate increase in patients with stable and progressing ischemic stroke.

Methods: Glutamate in CSF was measured by high-performance liquid chromatography in 184 patients with an acute cerebral infarction of less than 24 hours' duration and in 43 control subjects.

Results: Among the 120 patients with stable ischemic stroke, median glutamate levels were significantly lower- and within the reference range of control subjects-in those patients studied 6 to 24 hours from onset of symptoms than in patients studied in the first 6 hours (3 [range, 2 to 10] versus 5 mumol/L [range, 2 to 17]; P < .0001). In 64 patients with progressing ischemic stroke, glutamate concentrations measured at any time interval during the first 24 hours from onset were significantly higher than in the stable stroke and control groups.

Conclusions: The presence of glutamate increase in the CSF cannot be documented for greater than 6 hours in stable ischemic stroke. The sustained elevation of glutamate observed in progressing stroke suggests that the window to prevent neurological deterioration may be wider.

Citing Articles

The Study of the Protection Mechanism of Calycosin-7--β-d-Glucoside Against Oxygen-Glucose Deprivation/Reperfusion in HT22 Cells Based on Non-Targeted Metabolomics and Network Analysis.

Pei D, Huang J, Chen S, Deng Q, Nie C, Zhu L Molecules. 2025; 30(3).

PMID: 39942654 PMC: 11819903. DOI: 10.3390/molecules30030549.


Nelonemdaz and Patients With Acute Ischemic Stroke and Mechanical Reperfusion: The RODIN Randomized Clinical Trial.

Lee J, Kang H, Ahn S, Song T, Shin D, Bae H JAMA Netw Open. 2025; 8(1):e2456535.

PMID: 39874036 PMC: 11775734. DOI: 10.1001/jamanetworkopen.2024.56535.


The Cerebrovascular Side of Plasticity: Microvascular Architecture across Health and Neurodegenerative and Vascular Diseases.

Zedde M, Pascarella R Brain Sci. 2024; 14(10).

PMID: 39451997 PMC: 11506257. DOI: 10.3390/brainsci14100983.


Utilizing engineered extracellular vesicles as delivery vectors in the management of ischemic stroke: a special outlook on mitochondrial delivery.

Chen J, Li Y, Quan X, Chen J, Han Y, Yang L Neural Regen Res. 2024; 20(8):2181-2198.

PMID: 39101653 PMC: 11759020. DOI: 10.4103/NRR.NRR-D-24-00243.


Precision Medicine for Blood Glutamate Grabbing in Ischemic Stroke.

Hervella P, Sampedro-Viana A, Fernandez-Rodicio S, Rodriguez-Yanez M, Lopez-Dequidt I, Pumar J Int J Mol Sci. 2024; 25(12).

PMID: 38928260 PMC: 11204254. DOI: 10.3390/ijms25126554.